NeuroSense Therapeutics Ltd. (NRSN)

Price & Market Data

Price: $0.84

Daily Change: +$0.067 / 7.98%

Daily Range: $0.767 - $0.84

Market Cap: $29,601,846

Daily Volume: 66,930

Performance Metrics

1 Week: -6.05%

1 Month: 11.23%

3 Months: -9.66%

6 Months: -25.15%

1 Year: -46.61%

YTD: 0.11%

About NeuroSense Therapeutics Ltd. (NRSN)

Your comprehensive guide to NeuroSense Therapeutics Ltd. (NRSN). Price: 0.84, daily change: +$0.067 / 7.98%. Market cap: 29,601,846. Full range of performance data for investors.

Company Details

Employees: 16

Sector: Health technology

Industry: Pharmaceuticals: major

Country: Israel

Details

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Selected stocks

Dogwood Therapeutics, Inc. (DWTX)

VerifyMe, Inc. (VRME)

Bullfrog AI Holdings, Inc. (BFRG)

Forward Industries, Inc. (FWDI)

Brandywine Realty Trust (BDN)